FDA, CDC opens investigation into cronobacter and salmonella complaints in infant formula
The US Food and Drug Administration (FDA) and CDC (Centers for Disease Control and Prevention) are looking into 4 complaints about illness linked to Abbott Nutrition formula produced in a Michigan factory.
The US Food and Drug Administration has started an inspection of the Sturgis, Michigan Abbott Nutrition plant that manufactured powedered infant formula that has been linked to 3 reports of Cronobacter sakazakii infections and 1 report of Salmonella Newport infection in infants.1 All of the infants required hospitalization and 1 died.
The findings found so far include multiple positive C sakazakii results from samples. A review of records showed potential environmental contamination from C sakazakii as well as product that had been destroyed because of the presence of the bacteria.
Abbott Nutrition started a voluntary recall of the formula yesterday, February 17, 2022. The affected products are Similac, Alimentum, or EleCare with the following information that can be found on the bottom:
- the first two digits of the code are 22 through 37 and
- the code on the container contains K8, SH, or Z2, and
- the expiration date is 4-1-2022 (APR 2022) or later.
This article was published by our sister publication Contemporary Pediatrics.
Reference
1. US Food and Drug Administration. FDA investigation of Cronobacter and Salmonella complaints: powdered infant formula. Published February 18, 2022. Accessed February 18, 2022. https://www.fda.gov/food/outbreaks-foodborne-illness/fda-investigation-cronobacter-and-salmonella-complaints-powdered-infant-formula-february-2022
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
